Evidence map›Paper›PMID 35638570›Full record

ArticleJournal of cell science2022

HIV and FIV glycoproteins increase cellular tau pathology via cGMP-dependent kinase II activation.

Matheus F Sathler, Michael J Doolittle, James A Cockrell, India R Nadalin, Franz Hofmann, Sue VandeWoude, Seonil Kim

Open access · bronzeAbstract read
In one paragraph

Article in Journal of cell science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. The association between rs6859 inmedRxiv : the preprint server for health sciences · 2024
    Article
  9. Review
  10. Observational
  11. The association between rs6859 inFrontiers in aging neuroscience · 2024
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Matheus F SathlerDepartment of Biomedical Sciences, 1617 Campus Delivery, Colorado State University, Fort Collins, CO 80523, USA.
Michael J DoolittleMolecular, Cellular and Integrative Neurosciences Program, Colorado State University, Fort Collins, CO 80523, USA.
James A CockrellDepartment of Human Development and Family Studies, Colorado State University, Fort Collins, CO 80523, USA.
India R NadalinDepartment of Biomedical Sciences, 1617 Campus Delivery, Colorado State University, Fort Collins, CO 80523, USA.
Franz HofmannTechnical University of Munich, Arcisstraße 21, D-80333 Munich, Germany.
Sue VandeWoudeDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA.
Seonil KimDepartment of Biomedical Sciences, 1617 Campus Delivery, Colorado State University, Fort Collins, CO 80523, USA.ORCID 0000-0002-0451-2180
Colorado State University · USTechnical University of Munich · DE

Funding

NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
Recovery of Synaptic Dysfunction and Memory Loss in Alzheimer's Disease by Selective Co-Activation of Nicotinic Acetylcholine ReceptorsR03AG072102 · NIA · COLORADO STATE UNIVERSITY · PI KIM, SEONIL · 2021 to 2022
$304k
NCATS NIH HHS UL1 TR002535NIA NIH HHS R03 AG072102
6 · The paper itself

Abstract

As the development of combination antiretroviral therapy (cART) against human immunodeficiency virus (HIV) drastically improves the lifespan of individuals with HIV, many are now entering the prime age when Alzheimer's disease (AD)-like symptoms begin to manifest. It has been shown that hyperphosphorylated tau, a known AD pathological characteristic, is prematurely increased in the brains of HIV-infected individuals as early as in their 30s and that its levels increase with age. This suggests that HIV infection might lead to accelerated AD phenotypes. However, whether HIV infection causes AD to develop more quickly in the brain is not yet fully determined. Interestingly, we have previously revealed that the viral glycoproteins HIV gp120 and feline immunodeficiency virus (FIV) gp95 induce neuronal hyperexcitation via cGMP-dependent kinase II (cGKII; also known as PRKG2) activation in cultured hippocampal neurons. Here, we use cultured mouse cortical neurons to demonstrate that the presence of HIV gp120 and FIV gp95 are sufficient to increase cellular tau pathology, including intracellular tau hyperphosphorylation and tau release to the extracellular space. We further reveal that viral glycoprotein-induced cellular tau pathology requires cGKII activation. Taken together, HIV infection likely accelerates AD-related tau pathology via cGKII activation.

Indexed as

Alzheimer DiseaseHIV InfectionsImmunodeficiency Virus, FelineAnimalsCatsGlycoproteinsMiceNeuronstau ProteinsGlycoproteinstau ProteinsAlzheimer's diseaseCGMP-dependent kinase IIFeline immunodeficiency virusHuman immunodeficiency virusTau pathology

Identifiers

PMID35638570
PMCPMC9270957
OpenAlexW4281706725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.